KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to 15.61%.

  • Boston Scientific's EBIT Margin rose 8100.0% to 15.61% in Q4 2025 from the same period last year, while for Dec 2025 it was 18.0%, marking a year-over-year increase of 24500.0%. This contributed to the annual value of 18.0% for FY2025, which is 24600.0% up from last year.
  • As of Q4 2025, Boston Scientific's EBIT Margin stood at 15.61%, which was up 8100.0% from 20.69% recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's EBIT Margin ranged from a high of 20.69% in Q3 2025 and a low of 5.76% during Q4 2021
  • Over the past 5 years, Boston Scientific's median EBIT Margin value was 15.1% (recorded in 2022), while the average stood at 14.68%.
  • As far as peak fluctuations go, Boston Scientific's EBIT Margin skyrocketed by 209100bps in 2021, and later plummeted by -22300bps in 2024.
  • Boston Scientific's EBIT Margin (Quarter) stood at 5.76% in 2021, then soared by 115bps to 12.4% in 2022, then grew by 26bps to 15.68% in 2023, then fell by -6bps to 14.8% in 2024, then increased by 5bps to 15.61% in 2025.
  • Its EBIT Margin was 15.61% in Q4 2025, compared to 20.69% in Q3 2025 and 16.18% in Q2 2025.